Posts Tagged ‘New Jersey’

  • Celgene Pays $280 Million for Off-Label Marketing of Cancer Drugs

    Celgene, a pharmaceutical manufacturer based out of New Jersey, paid $280 million following a whistleblower suit which claimed they promoted their popular cancer drugs for unapproved purposes. The two drugs in question, Thalomid and Revlimid, are Celgene’s highest-grossing products, together accounting for $8.4 billion in annual revenue – an astounding 75% of the company’s profits. […]

  • First Federal Case of Its Kind Unveils $1.4 Million “Spoofing” Scheme

    The conception of the Dodd-Frank Wall Street Reform and Consumer Protection Act has come to fruition in the uncovering of a large-scale commodities exchange scheme, resulting in an estimated loss of $1.4 million. This scheme directly violated the anti-spoofing provision of the Dodd-Frank Act, and is being called the first of its kind to be […]

  • Subacute Nursing Home Provides Substandard Care

     A small-town nursing home in New Jersey recently agreed to pay a sum of $888,000 to resolve allegations that they had provided substandard or “worthless” care to patients over the course of a two-year Medicaid fraud scheme. From July 2010 to December 2012, Andover Subacute and Rehab Center Services Two Inc. billed New York Medicaid […]